Clinical Trial Update: Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tolvaptan effects on renal plasma flow and glomerular filtration rate in autosomal dominant polycystic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Kidney Disease Autosomal Dominant

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: Regional Hospital Holstebro | Conditions: Polycystic Kidney, Autosomal Dominant | Phase 3 | Status: COMPLETED